Scientists have identified a crucial interaction between IL-17RD and the interleukin-17 receptor that mediates signaling pathways. This discovery provides new insights into how chronic inflammation can lead to tumor development. The findings could pave the way for novel therapeutic approaches.
New Receptor Interaction Discovered in Inflammation Signaling
Researchers have uncovered a previously unknown mechanism in interleukin-17 (IL-17) signaling that may explain the link between chronic inflammation and cancer development, according to recent reports published in Cell Research. The study reveals that IL-17RD, also known as Sef or IL-17RLM, interacts directly with the IL-17 receptor and mediates crucial signaling pathways.